Objective-Pretubulysin (PT) is a novel, synthetically accessible myxobacterial compound that acts as a tubulindepolymerizing agent and inhibits cancer cell growth in vitro and in vivo. Moreover, PT was found to attenuate tumor angiogenesis. Here, we hypothesized that PT could exert antivascular activities on existing tumor vessels. Approach and Results-We aimed to characterize the antivascular effects of PT and to elucidate the underlying mechanisms in endothelial cells. In vitro, PT rapidly induced endothelial hyperpermeability and a concentration-dependent disassembly of established endothelial tubes on Matrigel and in an ex vivo aortic ring model. It disrupted endothelial cell junctions and triggered F-actin stress fiber formation and cell contraction by the RhoA/Rho-associated protein kinase pathway without causing cell death. In vivo, using a hamster dorsal skinfold chamber preparation, PT significantly decreased blood flow and vessel diameter in hamster A-Mel-3 amelanotic melanoma tumors but not in the neighboring healthy tissue. In a second tumor model using mice with subcutaneous murine B16 melanoma tumors, a single dose of PT (10 mg/kg) caused a shut down of tumor blood flow and a strong central tumor cell necrosis within 24 hours. Repeated PT administration significantly decelerates tumor growth and seems to be well tolerated. 
T umor growth and metastasis depend on a functional vascular network, which supplies the tumor with nutrients and oxygen. Therefore, targeting the tumor vasculature offers an interesting antitumor strategy, which has intensively been explored in recent years. Two different pharmacological approaches exist in this field: (1) the angiogenesis inhibitors, which are already clinically established, such as bevacizumab or sorafenib. They act on the periphery of small tumors and prevent neovascularization from existing blood vessels. (2) The vascular disrupting agents (VDAs), which have recently gained importance in experimental antitumor treatment, are effective well below their maximum tolerated dose and lack the classic cytotoxic side effects of chemotherapeutics. 1, 2 Their way of action completely differs from that of angiogenesis inhibitors: VDAs target the already established tumor blood vessels of larger solid tumors resulting either in apoptotic death of endothelial cells (ECs) or in cytoskeletal rearrangements, which alter the EC shape. 3, 4 These events emerge especially in the central part of the tumor and cause within a few hours after treatment strong hyperpermeability, vessel occlusion, shut down of tumor blood flow, ischemia, and enormous central necrosis, which can extend to as much as 95% of the tumor. 1, 5, 6 Thereby, a peripheral viable rim of tumor cells remains, which is responsible for the rapid regrowth after single-dose treatment. 4, 7 To overcome this obstacle, VDAs are commonly applied in combination with chemotherapy, radiation, or angiogenesis inhibitors, which promote suppression of regrowth. [8] [9] [10] Several VDAs are currently in clinical trials under intensive investigation, for example, combretastatin A-4 3-O-phosphate (CA4P) as well as its analogues OXi4503 and AVE8062. These are used as single compounds or in combination with other antivascular agents.
Pretubulysin (PT) represents a natural compound of myxobacterial origin, which was first isolated from Angiococcus disciformis An d48 in small amounts. 11 It is a biosynthetic precursor of the microtubule-depolymerizing peptide tubulysin, 11 which has been described recently to be highly active against different tumor cell lines. 12, 13 Structurally, PT is a linear tetrapeptide consisting of isoleucine and 3 unnatural amino acids. 11 In contrast to tubulysin, [14] [15] [16] [17] PT is synthetically more easily accessible; in 2009, PT was first synthesized in the gram scale by Ullrich et al. 18, 19 Although the structure of PT is less complex, it shows nearly the same microtubule-depolymerizing potency as tubulysin and is also able to inhibit tumor cell growth. 20 PT acts, like other tubulin-binding agents, through binding to the β-subunit of tubulin. 21 Besides inhibition of cancer cell growth, PT has been shown recently to attenuate tumor angiogenesis. 22 Here, we hypothesized that PT could also exert antivascular actions on already existing tumor vessels. Thus, we aimed to characterize the effects of PT in vitro in ECs and in vivo in different tumor models. Moreover, we investigated the underlying mechanisms of action.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

PT Triggers the Depolymerization of Microtubules, Actin Stress Fiber Formation, Disassembly of CellCell Connections, Endothelial Hyperpermeability, and the Destruction of Endothelial Tubes
PT treatment (30 and 300 nmol/L, 1 hour) induced the depolymerization of microtubules in primary EC ( Figure 1A , i-iii). Noteworthy, PT showed an extent of depolymerization comparable with CA4P ( Figure 1A , iv-vi). As shown in Figure 1B , PT (1 hour, 300 nmol/L) triggered the formation of thick, cellspanning F-actin stress fibers ( Figure 1B , i and ii) and the disruption of adherens junctions (vascular endothelial cadherin; Figure 1B , iii and iv) and tight junctions (claudin 5; Figure 1B , v and vi), thereby forming intercellular openings (marked by arrowheads). Focal adhesions showed a strong redistribution to pronounced clustered structures ( Figure 1B , vii and viii). These changes are accompanied by an increase in endothelial permeability as assessed by 2 different assays; a time-and concentration-dependent decrease in electric impedance (ie, increase of permeability) was observed already on a few minutes of PT treatment reaching its minimum within 1.5 hours (100 nmol/L PT) or within 1 hour (300 nmol/L; Figure I in the online-only Data Supplement). The statistical evaluation of all tested concentrations at time point 1 hour is depicted in Figure 1C , i. A half maximal inhibitory concentration value of 71 nmol/L was calculated. In a second approach, macromolecular permeability (tracer: fluorescein isothiocyanate [FITC]-dextran, 40 kDa) was determined. Again, PT evoked a time-and concentration-dependent increase in permeability ( Figure 1C , ii and iii). Aiming to investigate the ability of PT to destroy established endothelial tubes, we observed a disassembly of PT-treated tubes starting at 1.5 hours after PT addition (data not shown), leading to an almost complete disruption within 6 hours at 100 nmol/L PT ( Figure 1D , i-vi). The total tube lengths, as well as the total number of tubes and of branching points, were strongly reduced by PT after 6 hours ( Figure 1D , vii-ix). Moreover, established endothelial tubes that had sprouted from explanted mouse aortic rings were also significantly disrupted by PT (300 nmol/L) after 3 and 6 hours ( Figure 1E , marked by arrowheads). (Figure 2A ) and led to a reduction of ≈20% within 26 hours ( Figure 2B ). The basal apoptosis rate of untreated cells (≈6%) was slightly increased by PT (24 hours) to ≈10% ( Figure 2C) , and also the number of membranedamaged PI-positive cells rose from 5% to ≈15% ( Figure 2D ). Interestingly, removal of PT after 1 and 24 hours of treatment led to a full reestablishment of the normal EC morphology within 24 hours ( Figure 2E ). We conclude that short-term PT treatment is not toxic and that the slight cytotoxicity induced on 24 hours is fully reversible. Figure 3B ) and by Western blot analysis ( Figure 3C ) of the MLC (Thr18/Ser19) phosphorylation status. This status is regulated by activation of the MLC kinase (MLCK) and by inactivation of the MLC phosphatase (MLCP). Interestingly, the MLCK inhibitor ML-7 did not alter the PT-evoked phosphorylation of MLC ( Figure 3D ). Further, the MLCP activation status was not affected by PT, as judged by analyzing the phosphorylation of the MLCP subunit myosin phosphatase targeting protein 1 ( Figure 3E ). This indicates that neither MLCK nor MLCP is involved in PT-induced signaling. However, on pretreatment of ECs with the Rho-associated protein kinase (ROCK) inhibitor Y27632, both the PT-induced MLC phosphorylation and stress fiber formation were completely prevented ( Figure 3F ). Moreover, we tested whether endothelial calcium levels were affected by PT treatment. Ratiometric calcium imaging in Fura 2-loaded ECs showed that cytosolic calcium concentrations were not influenced by PT ( Figure 3G ). Histamine was applied as positive control to confirm that ECs respond in a normal way to this calcium-augmenting autacoid. Besides Rho signaling, we also investigated whether the p38 mitogen-activated protein kinase (MAPK) pathway participates in stress fiber formation because we found a strong phosphorylation (activation) of this kinase and of its downstream target heat shock protein 27 within 30 minutes on PT treatment ( Figure 3H ). However, after applying the p38 MAPK inhibitor SB202580 (functionality was proven and is shown in Figure IV in the online-only Data Supplement), PT was still able to exert its action on the actin cytoskeleton ( Figure 3I ). These data suggest that the effects of PT are mainly mediated by the RhoA/ROCK pathway, but not via calcium, MLCK, MLCP, or p38 MAPK.
Short-Term
PT Triggers Its Effects on Endothelial
PT Selectively Reduces Tumor Blood Flow in a Hamster Dorsal Skinfold Chamber Model
First, we determined the maximum tolerated dose of PT in a separate in vivo approach in mice. We revealed 10 mg/ kg PT as the optimal dose ( Figure with 300 nmol/L PT. After removal of PT, cells were washed and fresh growth medium was added. After 24-hour incubation without PT (iii and iv), the same well was photographed using bright field microscopy. Magnification, ×10 (for all panels).
openings. One representative experiment of 3 is shown. Bars for B (i to vi), 50 μm and B (vii and viii), 20 μm. C, Changes in permeability on PT treatment were measured by impedance sensing (i) and by a macromolecular permeability assay (ii and iii). C, i, Human microvascular endothelial cells (HMECs) were grown to confluence on gold electrodes and treated as indicated. Impedance was measured every 10 seconds up to 12 hours. Quantitative analysis was performed at time point 1 hour after PT treatment (PT, mean±SEM, n=4). C, ii, Confluent HMEC monolayer grown on porous filter inserts were treated with vehicle control (• ), 30 nmol/L PT (▲), 100 nmol/L PT (▼), and 300 nmol/L PT (♦). Fluorescein isothiocyanate (FITC)-labeled dextran (40 kDa) was added to the upper compartment of the chamber. After 30, 60, 120, and 240 minutes the amount of FITC-dextran in the lower compartment of the chamber was determined. Quantitative analysis (iii) was performed at time point 4 hours. Control values were set as 1. Data are expressed as mean±SEM, n=4 (i), n=3 (ii and iii). One-way ANOVA followed by Tukey's multiple comparison post hoc test was used. *P≤0.05 vs control. D, HUVECs were seeded on Matrigel. After 16 hours, endothelial tubes were formed, which were then treated as indicated. Phasecontrast images before (i-iii) and after 6 hours of treatment (iv-vi) were taken. Magnification, ×10 for all panels. Tube disruption was quantified at time point 6 hours after PT treatment. Total tube length (vii), total tubes (viii), and total branching points (ix) were chosen for analysis. Control values were set as 100%. Bar graph data are expressed as mean±SEM and were obtained from 6 independent experiments. One-way ANOVA followed by Tukey's multiple comparison post hoc test was used. *P≤0.05 vs control. E, Fourteen aortic rings prepared from 6 different female C57BL/6 mice were placed on Matrigel. After 10 days established endothelial sprouts were treated with 300 nmol/L PT and phase-contrast images before (i), after 3 hours (ii), and after 6 hours (iii) of treatment were taken. Arrowheads indicate disrupted sprouts (ii and iii). One representative experiment of 14 is shown. Magnification, ×10. Quantification was performed using ImageJ 1.45s software. Normalized data (0 hours) are expressed as mean±SEM (n=14). One-way ANOVA followed by Tukey's multiple comparison post hoc test was used. *P≤0.05 vs control (0 hours). CA4P indicates combretastatin A4-phosphate; IC 50 , half maximal inhibitory concentration; and VE, vascular endothelial. microvessel networks indicating nonperfused vessels, were seen. In contrast, the perfusion of vessels in the surrounding healthy tissue was not affected (Figure 4A , ii). The velocity of red blood cells, the diameter of the vessels, and the functional vessel density were quantified: all 3 parameters were significantly reduced in tumor blood vessels, but not in nontumor blood vessels ( Figure 4B ), whereas treatment with vehicle control had no effect ( Figure VI in the online-only Data Supplement). These data demonstrate that PT induces a rapid and selective shutdown of tumor blood flow in vivo.
PT Diminishes Tumor Vessel Perfusion, Induces Central Necrosis, and Decelerates Tumor Growth in an Ectopic B16-F1 Mouse Melanoma Tumor Model
C57BL/6 mice bearing subcutaneous, highly vascularized B16-F1 mouse melanoma tumors were treated with PT (intravenous injection, 10 mg/kg PT) as soon as the tumors had reached a size of ≈650 mm 3 . Twenty-four hours later, Hoechst 33342 was intravenously injected as perfusion marker and mice were euthanized after 1 minute. Both the tumor rim ( Figure 5A ) and the tumor center ( Figure 5B ) of PT-or vehicle-treated mice were analyzed. In control tumors, Hoechst 33342 (ie, perfusion) was detectable nearly in equal intensity at the rim as well as in the center, whereas PT-treated tumors showed a lesser Hoechst 33342 intensity at the rim and almost no staining in the center ( Figure 5A and 5B). For quantification, the ratio of Hoechst 33342 fluorescence and total number of CD31-positive cells is given in Figure 5C . CD31-positive ECs were similarly distributed throughout the tumors, indicating that tumor vessel density was not altered by PT ( Figure 5D ). Hematoxylin and eosin staining of these tumors revealed that PT treatment increases necrosis, which spanned ≈30% of the whole tumor area ( Figure 5E and 5F). In a second approach, PT treatment was started as soon as tumors reached a size of ≈100 mm 3 and was applied repeatedly (on days 0, 3, and 6). Thus, we determined both the overall capacity of PT to affect tumor growth and also its tolerability. We found that the increase of tumor size was strongly attenuated by PT was monitored using confluent HUVECs, which were incubated with Fura-2-AM for 30 minutes. Cells were then treated for 45 minutes with 300 nmol/L PT (gray line) or were left untreated (black line). At the end, histamine (100 μmol/L) was added as positive control. One representative figure of 3 is shown. ( Figure 5G ) and that the repeated application did not significantly influence the weight of the animals (data not shown). Taken together, our data demonstrate that a single dose of PT leads to a breakdown of tumor blood supply followed by excessive tumor necrosis. Moreover, repeated PT administration strongly decelerates tumor growth and is well tolerated.
Discussion
In this study, we present a preclinical characterization of the antivascular action of the myxobacterial tubulin-destabilizing compound PT by an in-depth investigation into the PT-induced effects on ECs in vitro and in different animal tumor models in vivo.
In vitro, we showed that the PT-triggered microtubule disassembly results in activation of RhoA, ROCK-mediated phosphorylation of MLC, actin stress fiber formation and activation of the contractile machinery, disassembly of interendothelial junctions, increase in permeability, and disruption of tube-like endothelial structures. Our study is in line with reports demonstrating that the disassembly of microtubules, for example, by CA4P or nocodazole, can activate the RhoA/ROCK/MLC pathway, which contributes to actin remodeling and hyperpermeability. [23] [24] [25] [26] Interestingly, it is still not clear how a disassembly of the tubulin network can activate RhoA, but it can be speculated that guanosine nucleotide exchange factors, which are linked to microtubules, 27, 28 could be involved. Recent studies showed that guanosine nucleotide exchange factor-H1, a Rho-specific guanosine nucleotide exchange factor, is inactive when it is bound to microtubules, whereas depolymerization results in its release and activation, accompanied by induction of stress fiber formation and MLC phosphorylation. 29 Besides the RhoA/ROCK/MLC pathway, also p38 MAPK, a known important regulator of actin remodeling 30, 31 was reported to be involved in the action of microtubule-disrupting compounds. 25, 26 In fact, we could show that p38 MAPK is strongly activated by PT. However, in contrast to these findings, activation of p38 MAPK is not needed to mediate the effects of PT on the F-actin cytoskeleton in our system. We speculate that the PT-induced activation of p38 MAPK might be associated with the process of early membrane blebbing, which was observed at higher concentrations of PT after long-term treatment (data not shown). Early membrane blebbing was intensively described by a study of Kanthou and Tozer, 23 in which they could show that membrane blebbing in human umbilical vein ECs (HUVECs) occurred on the disruption of microtubules. This phenomenon is dependent on the activation of p38 MAPK, but was independent of MLCK-mediated MLC phosphorylation and, remarkably, of apoptotic blebbing. 23 The PT-induced strong effects on cellular functions and morphology might at first suggest that PT is cytotoxic to the endothelium. However, cytotoxicity assays revealed that PT did neither strongly reduce metabolic activity nor heavily trigger apoptosis or necrosis after 24 hours. Furthermore, we could not detect any G2/M arrest (data not shown), which plays an important role in the onset of apoptosis-mediated cell death. Our findings are in contrast to data from previous studies, in which PT as well as CA4P was shown to induce G2/M shown. Magnification, ×4 (for both panels). Bar, 400 μm. F, Quantification of H&E staining. Two sections per H&E-stained tumor were photographed as described in the Materials and Methods. Quantification of necrotic areas was performed using ImageJ 1.45s software. Data are expressed as mean±SEM (PT, n=9; DMSO, n=6). Unpaired t test was used. *P≤0.05 vs Co. G, B16-F1 tumor growth was analyzed during a period of 7 days, with IV injection of a single dose of 10 mg/kg PT or 5% DMSO every third day (indicated by arrows). Increased tumor size is displayed as x-fold increase in tumor volume compared with the starting point (0 day). Data are expressed as mean±SEM (PT, n=6; DMSO, n=5). Unpaired t test was used. *P≤0.05 vs DMSO control.
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arrest and apoptosis within 24 to 48 hours. 3, 22, 32 The reason for these different results may be a result of the fact that we worked with confluent, quiescent HUVECs, whereas the mentioned studies used proliferating ones, which are susceptible to the blockade of the spindle apparatus. This is supported by our own experiments showing that proliferating HUVECs pretreated with PT reveal a 4× higher induction of apoptosis ( Figure II in the online-only Data Supplement) than confluent ones and a G2/M arrest (data not shown). Confluent HUVECs treated with CA4P also did not undergo changes in metabolic activity, G2/M arrest, apoptosis, or necrosis (data not shown). Moreover, HUVECs are even able to reassume their normal morphology after removing PT, which indicates that PT treatment exerts only minor cytotoxicity.
Using different in vivo tumor models, we showed that PT treatment induces a significant reduction in tumor blood perfusion, whereby perfusion of healthy tissue seems to be unaffected. We cannot exclude that normal blood vessels are not at all affected by PT, but we suggest that a mature endothelium covered by pericytes is more stable and, thus, resistant to PT treatment. This hypothesis is supported by a study showing that in vitro cocultures of ECs with smooth muscle cells are less affected by CA4P than ECs alone. 33 In addition, differences between tumor and normal vasculature in regard to blood flow, permeability, interstitial fluid pressure, proliferation rate, or modifications of tubulin and actin could contribute to the observed selectivity 34, 35 but are still a matter of debate. Reduced tumor vessel perfusion and, consequently, necrosis occurred mainly in tumor centers although vessel density was unchanged. This suggests that vessels in the tumor center are much less perfused, possibly because of constriction or local occlusion, which might occur through EC shape changes or early membrane blebbing. 4 The reduced blood velocity caused by PT might also evoke an increase in blood viscosity, which would also promote vessel occlusion. 36 Repeated applications of PT to tumor-bearing mice were intended to mimic a more therapeutical setting. Although this model does not allow to discriminate between effects of PT on cancer cells and on the tumor vasculature, the strong tumor growth-decelerating action of PT clearly demonstrates the overall anticancer potential of the compound. Importantly, the compound seems to be well tolerated because no obvious side effects were detected and the animals did not exhibit significant weight changes.
Our data might point toward a vascular disrupting activity of PT. However, it has to be mentioned that the in vivo data were gained at a dose of 10 mg/kg. As demonstrated, a 3-fold higher dose of PT is not tolerated anymore. Thus, 10 mg/kg seems to be (near) the maximum tolerated dose. VDAs are by definition active below their maximum tolerated dose. We did not establish the in vivo efficacy of lower doses of PT.
In summary, we characterized the antivascular action of PT on established tumor blood vessels, which is suggested as an important part of its overall anticancer effect. This natural compound of myxobacterial origin is synthetically accessible in large scales, which provides the opportunity for chemical modification. Thus, PT represents an interesting novel, tubulin-binding compound for further optimization into a vasculartargeting agent.
